196 related articles for article (PubMed ID: 9469456)
1. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
Wagner E; Platt JL; Frank MM
J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum.
Walpen AJ; Laumonier T; Aebi C; Mohacsi PJ; Rieben R
Xenotransplantation; 2004 Mar; 11(2):141-8. PubMed ID: 14962276
[TBL] [Abstract][Full Text] [Related]
3. Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin.
Lassiter HA; Speranza MJ; Hall RT; Meade V; Christensen RD; Parker CJ
J Perinatol; 1990 Mar; 10(1):27-31. PubMed ID: 2107285
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
Basta M; Kirshbom P; Frank MM; Fries LF
J Clin Invest; 1989 Dec; 84(6):1974-81. PubMed ID: 2687331
[TBL] [Abstract][Full Text] [Related]
5. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations.
Spycher M; Matozan K; Minnig K; Zehnder R; Miescher S; Hoefferer L; Rieben R
Vox Sang; 2009 Nov; 97(4):348-54. PubMed ID: 19656348
[TBL] [Abstract][Full Text] [Related]
6. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN.
Piepers S; Jansen MD; Cats EA; van Sorge NM; van den Berg LH; van der Pol WL
J Neuroimmunol; 2010 Dec; 229(1-2):256-62. PubMed ID: 20920831
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous immunoglobulin G on the deposition of immunoglobulin G and C3 onto type III group B streptococcus and Escherichia coli K1.
Lassiter HA; Robinson TW; Brown MS; Hall DC; Hill HR; Christensen RD
J Perinatol; 1996; 16(5):346-51. PubMed ID: 8915932
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
van den Berg RH; Faber-Krol MC; van de Klundert JA; van Es LA; Daha MR
J Immunol; 1996 Jun; 156(11):4466-73. PubMed ID: 8666822
[TBL] [Abstract][Full Text] [Related]
9. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement.
Verbrugh HA; Peterson PK; Nguyen BY; Sisson SP; Kim Y
J Immunol; 1982 Oct; 129(4):1681-7. PubMed ID: 7108223
[TBL] [Abstract][Full Text] [Related]
10. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.
Skliris A; Happonen KE; Terpos E; Labropoulou V; Børset M; Heinegård D; Blom AM; Theocharis AD
Eur J Immunol; 2011 Feb; 41(2):437-49. PubMed ID: 21268013
[TBL] [Abstract][Full Text] [Related]
11. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro.
Mollnes TE; Andreassen IH; Høgåsen K; Hack CE; Harboe M
Mol Immunol; 1997 Jul; 34(10):719-29. PubMed ID: 9430199
[TBL] [Abstract][Full Text] [Related]
12. Anti-complement effects of lactoferrin-derived peptides.
Samuelsen Ø; Haukland HH; Ulvatne H; Vorland LH
FEMS Immunol Med Microbiol; 2004 Jun; 41(2):141-8. PubMed ID: 15145458
[TBL] [Abstract][Full Text] [Related]
13. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
[TBL] [Abstract][Full Text] [Related]
14. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway.
Basta M; Fries LF; Frank MM
Blood; 1991 Aug; 78(3):700-2. PubMed ID: 1859883
[TBL] [Abstract][Full Text] [Related]
15. Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations.
Ramasamy I; Tran E; Farrugia A
Biologicals; 1997 Mar; 25(1):87-92. PubMed ID: 9167012
[TBL] [Abstract][Full Text] [Related]
16. Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae.
Rainard P
Immunology; 1993 Aug; 79(4):648-52. PubMed ID: 8406591
[TBL] [Abstract][Full Text] [Related]
17. Anisakis simplex: the activity of larval products on the complement system.
García-Hernández P; Rodero M; Cuéllar C
Exp Parasitol; 2007 Jan; 115(1):1-8. PubMed ID: 16777096
[TBL] [Abstract][Full Text] [Related]
18. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
[TBL] [Abstract][Full Text] [Related]
19. The classical complement pathway plays a critical role in the opsonisation of uropathogenic Escherichia coli.
Li K; Sacks SH; Sheerin NS
Mol Immunol; 2008 Feb; 45(4):954-62. PubMed ID: 17870166
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of complement activation by a secreted Staphylococcus aureus protein.
Lee LY; Höök M; Haviland D; Wetsel RA; Yonter EO; Syribeys P; Vernachio J; Brown EL
J Infect Dis; 2004 Aug; 190(3):571-9. PubMed ID: 15243934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
